Damora Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Damora Therapeutics (DMRA).

Price Target Range — 3 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$47Upside to Avg. PT+117.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$40
Sep 25, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$40→$60
Jul 30, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$35→$40
Jul 27, 2026	Jefferies	Akash Tewari	Initiate	Buy	$50
Jul 21, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$45
Jun 12, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$35
Jun 11, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$45
May 28, 2026	Wedbush	David Nierengarten	Initiate	Outperform	$35
Apr 24, 2026	RBC Capital	Brian Abrahams	Initiate	Outperform	$40
Mar 25, 2026	Evercore ISI Group	Gavin Clark-Gartner	Initiate	Outperform	$46

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $40 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60

Guggenheim analyst Brad Canino maintains Damora Therapeutics (NASDAQ:DMRA) with a Buy and raises the price target from $40 to $60.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

Wedbush analyst David Nierengarten maintains Damora Therapeutics (NASDAQ:DMRA) with a Outperform and raises the price target from $35 to $40.

Benzinga Newsdesk

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.

Avi Kapoor

This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Wall Street analysts change outlook on top stocks, including LIME, CIFR, BSP, DMRA, and ITG. Check analyst ratings page for full view.

Avi Kapoor

PRO
Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

Jefferies analyst Akash Tewari initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy rating and announces Price Target of $50.

Benzinga Newsdesk

Damora Therapeutics Inc

Damora Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

PRO
Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60

PRO
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

People Also Watch

People Also Watch

Damora Therapeutics Inc

Damora Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

PROGuggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60

PROWedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROJefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

People Also Watch

People Also Watch

PRO
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

PRO
Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60

PRO
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

PRO
Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50